An $85 million 5-year initiative funded by the National Heart, Lung, and Blood Institute and the National Human Genome Research Institute will focus on developing induced pluripotent stem cells (iPSCs) from patients with genetic variants associated with heart disease and other disorders to explore the role such variants play in disease processes. Unlike natural stem cells, iPSCs are typically derived from an adult cell and are genetically manipulated into an embryonic stem cell–like state.
Kuehn BM. In Vitro Disease Studies. JAMA. 2011;306(8):815. doi:10.1001/jama.2011.1197